Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.37 |
| ▸ | ICMT | O60725 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 3/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956084 | 0.85 | NOTUM (0.39) | NOTUMMDM2ICMTCNR2KMT2A | |
| SCHEMBL2973653 | 0.77 | LDHA (0.37) | NOTUMKMT2ALMNA | |
| SCHEMBL5518087 | 0.72 | ALDH1A1 (0.43) | — | |
| SCHEMBL9956059 | 0.71 | KMT2A (0.33) | NOTUMKMT2A | |
| SCHEMBL25254402 | 0.70 | HDAC1 (0.33) | NOTUM | |
| SCHEMBL6401221 | 0.70 | CDC25A (0.40) | CNR2KMT2ACNR1 | |
| SCHEMBL9955513 | 0.70 | TP53 (0.36) | CNR2KMT2ACNR1LMNA | |
| SCHEMBL4733870 | 0.69 | NOTUM (0.42) | NOTUMMDM2ICMTP2RY14LMNA | |
| SCHEMBL4846231 | 0.69 | KMT2A (0.44) | KMT2ALMNA | |
| SCHEMBL23498965 | 0.69 | TP53 (0.44) | NOTUMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| CN-104529827-B | Ingenol-3-acylate III and ingenol-3-carbamate | 利奥实验室有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-103402977-B | Ingenol-3-acylate III and ingenol-3-carbamate | LEO PHARMA A/S (IE) | 2016-01-20 | — | — | CN | disclosed |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2015-10-15 | — | — | US | disclosed |
| US-9102687-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| CN-104529827-A | Ingenol-3-acylates III and ingenol-3-carbamates | LEO PHARMA AS | 2015-04-22 | — | — | CN | disclosed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| CN-103402977-A | Ingenol-3-acylate III and Ingenol-3-carbamate | LEO PHARMA AS | 2013-11-20 | — | — | CN | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | NOTUM 3011/4885MDM2 2270/4885ICMT 4410/4885 |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | NOTUM 3011/4885MDM2 2270/4885ICMT 4410/4885 |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | NOTUM 3011/4885MDM2 2270/4885ICMT 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.